无症状颈动脉狭窄筛查的临床效果与成本效益:一项马尔可夫模型
该研究用马尔可夫模型从终生视角评估超声筛查无症状颈动脉狭窄并随后启动预防治疗与不筛查相比的临床效果和成本效益。筛查的ICER为每获得1个增量质量调整生命年5744欧元,在50000欧元/QALY的支付意愿阈值下,最佳药物治疗需使卒中风险至少降低22%筛查才具成本效益。
要点
- 筛查的ICER为每获得1个QALY 5744欧元
- 每10万筛查者卒中绝对风险降低135例,需筛查人数741
- 在50000欧元/QALY阈值下,最佳药物治疗需降低卒中风险≥22%
核心结论
- 在50000欧元/QALY的支付意愿阈值下,无症状颈动脉狭窄筛查策略需最佳药物治疗使卒中风险中度降低22%才具成本效益。
- 针对无症状颈动脉狭窄患病率更高的人群可能进一步改善成本效益。
研究设计与样本
- 研究采用终生视角的马尔可夫模型,比较超声筛查无症状颈动脉狭窄后启动预防治疗与不筛查的临床效果和成本效益。
- 关键参数包括卒中风险、全因死亡率和成本,基于当代已发表数据、人口统计资料及瑞典乌普萨拉县(人口30万)一项正在进行的筛查项目数据。
- 无症状颈动脉狭窄患病率(2%)和最佳药物治疗率(40%)基于近期接受无症状颈动脉狭窄筛查的瑞典男性人群数据。
主要发现
- 筛查具成本效益,ICER为每获得1个增量质量调整生命年5744欧元。
- 每10万筛查者卒中绝对风险降低135例,需筛查人数为741,每10万受邀者获得6700个QALY。
- 在50000欧元/QALY的支付意愿阈值下,最佳药物治疗所需的最低卒中风险降低幅度为22%。
- 假设的卒中风险降低程度是成本效益最重要的决定因素。
关键数值与推荐
- 在支付意愿阈值为50000欧元/QALY时,最佳药物治疗所需的最低卒中风险降低幅度为22%。
- 筛查的ICER为每获得1个增量质量调整生命年5744欧元。
- 每10万筛查者卒中绝对风险降低135例,需筛查人数741,每10万受邀者获得6700个QALY。
临床怎么用
- 作者认为,在50000欧元/QALY的支付意愿阈值下,无症状颈动脉狭窄筛查策略需最佳药物治疗使卒中风险中度降低22%才具成本效益。
- 作者认为,针对无症状颈动脉狭窄患病率更高的人群可能进一步改善成本效益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: The cost-effectiveness of screening depends on the cost of screening, prevalence of asymptomatic carotid artery stenosis (ACAS), and the potential effect of medical intervention in reducing the risk of stroke. The aim of the study was to determine the threshold values for these parameters in order for screening for ACAS to be cost-effective. METHODS: The clinical effect and cost-effectiveness of ultrasound screening for ACAS with subsequent initiation of preventive therapy versus not screening was assessed in a Markov model with a lifetime perspective. Key parameters, including stroke risk, all cause mortality, and costs, were based on contemporary published data, population statistics, and data from an ongoing screening program in Uppsala county (population 300,000), Sweden. Prevalence of ACAS (2%) and the rate of best medical treatment (BMT; 40%) were based on data from a male Swedish population recently screened for ACAS. The required stroke risk reduction from BMT, incremental cost-efficiency ratio (ICER), absolute risk reduction for stroke (ARR), and number needed to screen (NNS) were calculated. RESULTS: Screening was cost-effective at an ICER of €5744 per incremental quality adjusted life year (QALY) gained. ARR was 135 per 100,000 screened, NNS was 741, and QALYs gained were 6700 per 100,000 invited. At a willingness to pay (WTP) threshold of €50,000 per QALY the minimum required stroke risk reduction from BMT was 22%. The assumed degree of stroke risk reduction was the most important determinant of cost-efficiency. CONCLUSION: A moderate (22%) reduction in the risk of stroke was required for an ACAS screening strategy to be cost-effective at a WTP of €50,000/QALY. Targeting populations with a higher prevalence of ACAS could further improve cost-efficiency.
引用
- Högberg D, Mani K, Wanhainen A, et al. Clinical Effect and Cost-Effectiveness of Screening for Asymptomatic Carotid Stenosis: A Markov Model. Eur J Vasc Endovasc Surg. 2018. PMID: 29636252. doi:10.1016/j.ejvs.2018.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。